There is a large amount of domestic manufacturing, including packaging, that is used in development. When product goes to production for market (not pre-market production) alternate supply chains are qualified to reduce costs.
The manufacturing sites and the supply chains are already qualified, the processes validated. This is not as big as an issue for us, as it is for them.
The manufacturing sites and the supply chains are already qualified, the processes validated.
Yes, but do those manufacturing sites and the supply chains keep on making the newly developed product, and for how long? Or do they go on to the next product to develop once the cheaper suppliers are up to speed?
What I'm getting at is how much production capacity really exists in the US, and how fast can additional production lines be themselves produced? Maybe it's different in Big Pharma, but my experience in "modest" manufacturing (mostly 100 to 300 employee plants) is that creating new production lines, esp. if a new or renovated-to-purpose building is required, is not exactly snap-your-fingers stuff. WW2 timelines would be disastrous for millions of our meds-dependent population.